These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 6308149)

  • 41. Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue.
    Reisine TD; Rossor M; Spokes E; Iversen LL; Yamamura HI
    Adv Biochem Psychopharmacol; 1980; 21():443-50. PubMed ID: 6246753
    [No Abstract]   [Full Text] [Related]  

  • 42. Central deopaminergic receptor supersensitivity and its relevance to Parkinson's disease.
    Pycock CJ; Marsden CD
    J Neurol Sci; 1977; 31(1):113-21. PubMed ID: 833607
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic pharmacological manipulation of dopamine receptors in brain.
    Jenner P; Marsden CD
    Neuropharmacology; 1987 Jul; 26(7B):931-40. PubMed ID: 2889159
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Neuroendocrine correlations in the pathogenesis and pathology of Parkinson disease].
    Pinessi L; Sabbatini F; De Mattei M; Gentile S
    Minerva Med; 1984 Nov; 75(42):2539-42. PubMed ID: 6096765
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prolactin secretion in Parkinson disease.
    Eisler T; Thorner MO; MacLeod RM; Kaiser DL; Calne DB
    Neurology; 1981 Oct; 31(10):1356-9. PubMed ID: 6810204
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential stereoselectivity of methotrimeprazine enantiomers for selected central nervous system receptor types.
    Robert TA; Hagardorn AN; Daigneault EA
    Mol Pharmacol; 1982 Mar; 21(2):315-9. PubMed ID: 6285167
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alterations in brain opiate receptors in Parkinson's disease.
    Reisine TD; Rossor M; Spokes E; Iversen LL; Yamamura HI
    Brain Res; 1979 Sep; 173(2):378-82. PubMed ID: 226215
    [No Abstract]   [Full Text] [Related]  

  • 48. Transmitter receptor alterations in Parkinson's disease.
    Calne DB; Stoessl AJ
    Adv Neurol; 1987; 45():45-9. PubMed ID: 2881449
    [No Abstract]   [Full Text] [Related]  

  • 49. The fluctuating Parkinsonian patient--clinical and pathophysiological aspects.
    Blanchet PJ
    Can J Neurol Sci; 2003 Mar; 30 Suppl 1():S19-26. PubMed ID: 12691473
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of D-1 and D-2 receptors.
    Schachter M; Bédard P; Debono AG; Jenner P; Marsden CD; Price P; Parkes JD; Keenan J; Smith B; Rosenthaler J; Horowski R; Dorow R
    Nature; 1980 Jul; 286(5769):157-9. PubMed ID: 7402308
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Receptor basis for dopaminergic supersensitivity in Parkinson's disease.
    Lee T; Seeman P; Rajput A; Farley IJ; Hornykiewicz O
    Nature; 1978 May; 273(5657):59-61. PubMed ID: 692671
    [No Abstract]   [Full Text] [Related]  

  • 52. Stimulation of 3H-apomorphine binding by dopamine and bromocriptine.
    Robertson HA
    Eur J Pharmacol; 1980 Jan; 61(2):209-11. PubMed ID: 7353592
    [No Abstract]   [Full Text] [Related]  

  • 53. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings).
    Birkmayer W; Riederer P
    J Neural Transm; 1975; 37(2):175-82. PubMed ID: 1185162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. "Catecholamines" in the brain.
    Cotzias GC
    N Engl J Med; 1970 Feb; 282(9):513. PubMed ID: 5411875
    [No Abstract]   [Full Text] [Related]  

  • 55. ECT, opioid system, and motor response in Parkinson's disease .
    Sandyk R
    Biol Psychiatry; 1986 Feb; 21(2):235-6. PubMed ID: 3004611
    [No Abstract]   [Full Text] [Related]  

  • 56. Opioid-dopamine interactions: implications for substance use disorders and their treatment.
    Volkow ND
    Biol Psychiatry; 2010 Oct; 68(8):685-6. PubMed ID: 20888455
    [No Abstract]   [Full Text] [Related]  

  • 57. L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.
    Guttman M; Seeman P
    J Neural Transm; 1985; 64(2):93-103. PubMed ID: 2934514
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment.
    Rinne UK; Rinne JO; Rinne JK; Laakso K; Laihinen A; Lönnberg P
    J Neural Transm Suppl; 1983; 18():279-86. PubMed ID: 6308149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Brain neurotransmitters and neuropeptides in Parkinson's disease.
    Rinne UK; Rinne JO; Rinne JK; Laakso K; Lönnberg P
    Acta Physiol Pharmacol Latinoam; 1984; 34(3):287-99. PubMed ID: 6099688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brain enkephalin receptors in Parkinson's disease.
    Rinne UK; Rinne JK; Rinne JO; Laakso K; Tenovuo O; Lönnberg P; Koskinen V
    J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.